Alexander Kokkinos Carel Le Roux To view or add a comment, sign in Tirzepatide: Redefining Outcomes in Diabetes & Obesity Care Clinical trials show tirzepatide, a dual GIP/GLP-1 receptor agonist, is delivering results beyond expectations: Up to 20.9% mean weight loss at 72 weeks (SURMOUNT-1, NEJM) 94% risk reduction in progression from prediabetes to type 2 diabetes over 3 years Superior HbA1c reduction and weight control vs leading GLP-1 therapies (SURPASS program) With manageable side effects and durable outcomes, tirzepatide is reshaping how we approach metabolic disease
Week 5-6: Optimization Phase Maintain therapeutic dose and add resistance training 3x weekly
Staying consistent with the regimen is crucial for optimal results
Many Americans May Need More Potassium White Plains, New York, November 15, 2016 During a recent analysis of potassium supplements sold in the U.S
For home use, the CapillusUltra Mobile Laser Therapy Cap comes highly recommended for its convenience and effectiveness in delivering red-light therapy for scalp health
Peptides can also support weight management, muscle growth, faster recovery, improved sleep, and higher energy levels
